ACR (American College of Rheumatology) is a society covering all immune-related diseases, and this year's conference is scheduled to be held at the San Diego Convention Center from November 10 to 15.
This poster presentation will feature preclinical results for an osteoarthritis pain-inhibiting compound, part of RudaCure's RCI002 project currently under development. The results to be presented demonstrate pain suppression for up to two weeks following a single administration.
Through formulation research, this compound is expected to be applicable not only for osteoarthritis but also for degenerative disc disease (cervical and lumbar spine, etc.) with administration once every six months or once a year.
